148 related articles for article (PubMed ID: 9458093)
1. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
[TBL] [Abstract][Full Text] [Related]
3. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
Agarwal VR; Bischoff ED; Hermann T; Lamph WW
Cancer Res; 2000 Nov; 60(21):6033-8. PubMed ID: 11085524
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
[TBL] [Abstract][Full Text] [Related]
5. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
6. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
Bischoff ED; Heyman RA; Lamph WW
J Natl Cancer Inst; 1999 Dec; 91(24):2118. PubMed ID: 10601384
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
Song JI; Lango MN; Hwang JD; Drenning SD; Zeng Q; Lamph WW; Grandis JR
Cancer Res; 2001 Aug; 61(15):5919-25. PubMed ID: 11479234
[TBL] [Abstract][Full Text] [Related]
8. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
Cohen LA; Pittman B; Wang CX; Aliaga C; Yu L; Moyer JD
Cancer Res; 2001 Dec; 61(24):8683-8. PubMed ID: 11751385
[TBL] [Abstract][Full Text] [Related]
9. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
[TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis.
Osborne MP; Ruperto JF; Crowe JP; Rosen PP; Telang NT
Cancer Res; 1992 Mar; 52(6):1477-80. PubMed ID: 1540955
[TBL] [Abstract][Full Text] [Related]
11. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
13. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen.
Anzano MA; Byers SW; Smith JM; Peer CW; Mullen LT; Brown CC; Roberts AB; Sporn MB
Cancer Res; 1994 Sep; 54(17):4614-7. PubMed ID: 8062253
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.
Moon RC; Kelloff GJ; Detrisac CJ; Steele VE; Thomas CF; Sigman CC
Anticancer Res; 1992; 12(4):1147-53. PubMed ID: 1386970
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
[TBL] [Abstract][Full Text] [Related]
16. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
17. A Phase I study of LGD1069 in adults with advanced cancer.
Rizvi NA; Marshall JL; Dahut W; Ness E; Truglia JA; Loewen G; Gill GM; Ulm EH; Geiser R; Jaunakais D; Hawkins MJ
Clin Cancer Res; 1999 Jul; 5(7):1658-64. PubMed ID: 10430065
[TBL] [Abstract][Full Text] [Related]
18. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
Kim MJ; Deplewski D; Ciletti N; Michel S; Reichert U; Rosenfield RL
Mol Genet Metab; 2001 Nov; 74(3):362-9. PubMed ID: 11708867
[TBL] [Abstract][Full Text] [Related]
19. Chemoendocrine therapy in DMBA-induced rat mammary carcinoma.
Morimoto T; Yamamoto H; Komaki K; Konishi N; Tanaka T; Yamakawa T; Mori T; Sasa M; Monden Y
Tokushima J Exp Med; 1990 Dec; 37(3-4):59-68. PubMed ID: 2128782
[TBL] [Abstract][Full Text] [Related]
20. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
Suh N; Wang Y; Williams CR; Risingsong R; Gilmer T; Willson TM; Sporn MB
Cancer Res; 1999 Nov; 59(22):5671-3. PubMed ID: 10582681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
